L-N6-[1-iminoethyl]lysine | 1635-05-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: L-N6-[1-iminoethyl]lysine
• 英文别名: N-iminoethyl-L-lysine；ε-N-Ethyl-L-lysin；N~6~-Ethyl-L-lysine；(2S)-2-amino-6-(ethylamino)hexanoic acid
• CAS: 1635-05-8
• 化学式: C₈H₁₈N₂O₂
• 分子量: 174.243
• InChiKey: PJWAKMZYPDSMFR-ZETCQYMHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.2
• 重原子数：
  12
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  75.4
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  (S)-2-amino-6-(4-methylphenylsulfonamido)hexanoic acid 、 碘乙烷 生成 L-N6-[1-iminoethyl]lysine
  参考文献：
  名称：

  氨基酸和肽：II。ε-N-甲基-L-赖氨酸及相关化合物的合成

  摘要：

  eN-甲基-L-赖氨酸、eN-乙基-L-赖氨酸和δ-N-甲基-L-鸟氨酸已通过α-N-苯甲酰基-ω-Np-甲苯磺酰氨基酸的烷基化合成。eN-甲基-L-赖氨酸也由...

  DOI：

  10.1139/v64-301

文献信息

• POTENT AND SELECTIVE INHIBITORS OF NAV1.7
  申请人：AMGEN INC

  公开号：US20160024159A1

  公开（公告）日：2016-01-28

  Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted Na V 1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of Na V 1.7. Other embodiments are conjugated embodiments of the inventive composition of matter and pharmaceutical compositions containing the inventive composition of matter. Isolated nucleic acids encoding some embodiments of inventive polypeptides and expression vectors, and recombinant host cells containing them are disclosed. A method of treating or preventing pain is also disclosed.

  本文揭示了一种物质组合物，包括一种孤立的多肽，该多肽是一种外周限制的NaV1.7抑制剂。在一些公开的实施方式中，这种孤立的多肽是NaV1.7的抑制剂。其他实施方式是该物质组合物的共轭实施方式和含有该物质组合物的药物组合物。还揭示了编码一些创新多肽的孤立核酸和表达载体以及含有它们的重组宿主细胞。还揭示了一种治疗或预防疼痛的方法。
• Process for preparing modified protein compositions
  申请人：TERUMO CORPORATION

  公开号：EP0047879A1

  公开（公告）日：1982-03-24

  The present invention provides a process for preparing a modified protein composition in which the amino acid constitution of a protein raw material is modified by preparing a dispersion of a given concentration of the protein raw material having a protease dissolved therein, esterifying an amino acid in an alcohol in the presence of a sulfuric acid catalyst to form an amino acid ester reaction solution, and adding the amino acid ester reaction solution to the dispersion to cause the protease to act on the protein raw material to give rise to the reverse reaction of proteolysis, thereby incorporating the amino acid into the protein in the form of a peptide bond.

  本发明提供了一种制备改性蛋白质组合物的工艺，在该工艺中，通过制备溶有蛋白酶的给定浓度的蛋白质原料分散液来改性蛋白质原料的氨基酸组成、在硫酸催化剂存在下，将氨基酸在醇中酯化，形成氨基酸酯反应溶液，然后将氨基酸酯反应溶液加入分散液中，使蛋白酶作用于蛋白质原料，引起蛋白水解的逆反应，从而将氨基酸以肽键的形式结合到蛋白质中。
• GLYCOPEPTIDE ANTIBIOTIC MONOMER DERIVATIVES
  申请人：National University Corporation Nagoya University

  公开号：EP1818340A1

  公开（公告）日：2007-08-15

  Novel glycopeptide antibiotic derivatives. These derivatives are represented by the formula (aglycon part of glycopeptide antibiotic derivative)-(Sac-NH)-RA [wherein (aglycon part of glycopeptide antibiotic derivative) is the part formed by removing the sugar part from a known glycopeptide antibiotic derivative; (Sac-NH) part is an amino sugar part or a sugar chain part containing an amino sugar; and RA represents, e.g., the formula -X1-Ar1-X2-Y-X3-Ar2 (wherein X1, X2, and X3 each represents 1) a single bond or 2) a heteroatom or heteroatom-containing group selected from the group consisting of -N=, =N-, -NR1-, -O-, etc.; Y represents -NR2CO- or -CONR2- (wherein R2 represents hydrogen or lower alkyl), etc.)]. These derivatives have antibacterial activity against vancomycin-resistant bacteria.

  新型糖肽抗生素衍生物。这些衍生物由式（糖肽抗生素衍生物的苷元部分）-(Sac-NH)-RA 表示[其中，（糖肽抗生素衍生物的苷元部分）是从已知的糖肽抗生素衍生物中去除糖部分而形成的部分；(Sac-NH)部分是氨基糖部分或含有氨基糖的糖链部分；RA 表示，例如、式-X1-Ar1-X2-Y-X3-Ar2（其中 X1、X2 和 X3 各自代表 1）单键或 2）选自-N=、=N-、-NR1-、-O-等组成的杂原子或含杂原子的基团；Y 代表-NR2CO-或-CONR2-（其中 R2 代表氢或低级烷基）等）]。这些衍生物对耐万古霉素细菌具有抗菌活性。
• Compositions and methods for producing bioactive fusion proteins
  申请人：AMGEN INC.

  公开号：EP2738257A1

  公开（公告）日：2014-06-04

  Disclosed is a composition of matter involving a recombinant fusion protein comprising of a pharmacologically active protein partner, and a small pharmacologically inactive protein domain partner of human origin, such as but not limited to, a 10th fibronectin III domain, a SH3 domain, a SH2 domain, a CH2 domain of IgG1, a PDZ domain, a thrombospondin repeat domain, an ubiquitin domain, a leucine-rich repeat domain, a villin headpiece HP35 domain, a villin headpiece HP76 domain, or a fragment or modification of any of these. Also disclosed are nucleic acids (e.g., DNA constructs) encoding the fusion protein, expression vectors and recombinant host cells for expression of the fusion protein, and pharmaceutical compositions containing the recombinant fusion protein and a pharmaceutically acceptable carrier, and method of producing a pharmacologically active recombinant fusion protein.

  本发明公开了一种物质组合物，涉及一种重组融合蛋白，该蛋白由药理活性蛋白伴侣和来源于人类的小药理非活性蛋白结构域伴侣组成，例如但不限于第 10 个纤维粘连蛋白 III 结构域、SH3结构域、SH2结构域、IgG1的CH2结构域、PDZ结构域、thrombospondin重复结构域、泛素结构域、富亮氨酸重复结构域、绒毛顶端HP35结构域、绒毛顶端HP76结构域，或任何这些结构域的片段或修饰。还公开了编码融合蛋白的核酸（如DNA构建体）、表达载体和表达融合蛋白的重组宿主细胞、含有重组融合蛋白和药学上可接受的载体的药物组合物，以及生产具有药理活性的重组融合蛋白的方法。
• Carrier immunoglobulins and uses thereof
  申请人：Amgen Inc.

  公开号：EP2725034A1

  公开（公告）日：2014-04-30

  Disclosed is an isolated immunoglobulin. Also disclosed are pharmaceutical compositions and medicaments comprising the immunoglobulin, isolated nucleic acid encoding it, vectors, host cells, useful in methods of making it. In some embodiments the immunoglobulin comprises one to twenty-four pharmacologically active chemical moieties conjugated thereto, such as a pharmacologically active polypeptide.

  公开了一种分离的免疫球蛋白。还公开了药物组合物和药物，其中包括免疫球蛋白、编码免疫球蛋白的分离核酸、载体、宿主细胞以及制造免疫球蛋白的有用方法。在某些实施方案中，免疫球蛋白包括一至二十四个药理活性化学分子，如药理活性多肽。